Do analysts prefer SYRS or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Syros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts recommend CARM or VAXX?

Carisma Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CARM or VAXX more profitable?

Vaxxinity has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Vaxxinity N/A N/A N/A

Do analysts prefer ARDS or CARM?

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Aridis Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aridis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is ARDS or CARM more profitable?

Aridis Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Carisma Therapeutics -254.28% N/A -192.17%

Do analysts recommend NAVB or CARM?

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Navidea Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is NAVB or CARM more profitable?

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Carisma Therapeutics -254.28% N/A -192.17%

Carisma Therapeutics (CARM) Competitors

$0.0001 0.00 (0.00%)

As of 06/5/2026 12:49 PM Eastern

Compare

CARM vs. EVGN, SYRS, VAXX, ARDS, and NAVB

Should you buy Carisma Therapeutics stock or one of its competitors? MarketBeat compares Carisma Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carisma Therapeutics include Evogene (EVGN), Syros Pharmaceuticals (SYRS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "medical" sector.

How does Carisma Therapeutics compare to Evogene?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

In the previous week, Evogene had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Evogene and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Neutral

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Evogene	$3.85M	1.40	-$8.48M	-$1.39	N/A

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Carisma Therapeutics currently has a consensus target price of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-158.82%	-80.37%

Carisma Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Evogene has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Summary

Carisma Therapeutics beats Evogene on 9 of the 15 factors compared between the two stocks.

How does Carisma Therapeutics compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Syros Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Carisma Therapeutics	-254.28%	N/A	-192.17%

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Carisma Therapeutics	Neutral

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Syros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Carisma Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Carisma Therapeutics beats Syros Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Carisma Therapeutics compare to Vaxxinity?

Carisma Therapeutics (NASDAQ:CARM) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Carisma Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Vaxxinity has a beta of -79.33, meaning that its share price is 8,033% less volatile than the broader market.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Vaxxinity	Neutral

Carisma Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vaxxinity has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Vaxxinity	N/A	N/A	N/A

Vaxxinity has lower revenue, but higher earnings than Carisma Therapeutics. Vaxxinity is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Carisma Therapeutics beats Vaxxinity on 8 of the 13 factors compared between the two stocks.

How does Carisma Therapeutics compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Aridis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aridis Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aridis Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Aridis Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Carisma Therapeutics	-254.28%	N/A	-192.17%

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Carisma Therapeutics. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Carisma Therapeutics	Neutral

Aridis Pharmaceuticals has a beta of 44.97, indicating that its stock price is 4,397% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Summary

Carisma Therapeutics beats Aridis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Carisma Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Navidea Biopharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Carisma Therapeutics	-254.28%	N/A	-192.17%

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Summary

Carisma Therapeutics beats Navidea Biopharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4K	$2.96B	$6.68B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.55%
P/E Ratio	0.00	18.12	24.03	23.62
Price / Sales	0.00	286.06	519.33	112.45
Price / Cash	N/A	56.84	42.23	54.60
Price / Book	0.00	3.83	9.73	6.35
Net Income	-$60.48M	$75.85M	$3.57B	$337.59M
7 Day Performance	N/A	-1.85%	-1.26%	-2.51%
1 Month Performance	N/A	-7.67%	0.82%	-0.69%
1 Year Performance	N/A	14.97%	24.09%	25.37%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	2.3025 of 5 stars	$0.00 flat	$1.00 +999,900.0%	-99.9%	$4K	$10.77M	0.00	20
EVGN Evogene	0.7299 of 5 stars	$0.59 -13.6%	N/A	-44.7%	$5.95M	$3.85M	N/A	140	Gap Down High Trading Volume
SYRS Syros Pharmaceuticals	N/A	$0.00 +150.0%	N/A	-98.4%	$13K	$386K	N/A	120	Gap Up
VAXX Vaxxinity	N/A	$0.00 flat	N/A	+100.0%	$13K	N/A	N/A	90
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+100.0%	$11K	N/A	0.00	30	News Coverage Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, SYRS, VAXX, ARDS, and NAVB

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to Syros Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Vaxxinity?

Summary

How does Carisma Therapeutics compare to Aridis Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Navidea Biopharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, SYRS, VAXX, ARDS, and NAVB

How does Carisma Therapeutics compare to Evogene?

Does the media refer more to CARM or EVGN?

Which has preferable earnings and valuation, CARM or EVGN?

Do insiders & institutionals have more ownership in CARM or EVGN?

Do analysts recommend CARM or EVGN?

Is CARM or EVGN more profitable?

Which has more risk & volatility, CARM or EVGN?

Summary

How does Carisma Therapeutics compare to Syros Pharmaceuticals?

Is SYRS or CARM more profitable?

Does the media favor SYRS or CARM?

Do analysts prefer SYRS or CARM?

Which has more volatility & risk, SYRS or CARM?

Which has preferable valuation & earnings, SYRS or CARM?

Do institutionals and insiders hold more shares of SYRS or CARM?

Summary

How does Carisma Therapeutics compare to Vaxxinity?

Which has more volatility & risk, CARM or VAXX?

Does the media refer more to CARM or VAXX?

Do analysts recommend CARM or VAXX?

Is CARM or VAXX more profitable?

Which has higher valuation and earnings, CARM or VAXX?

Do institutionals & insiders believe in CARM or VAXX?

Summary

How does Carisma Therapeutics compare to Aridis Pharmaceuticals?

Do institutionals & insiders have more ownership in ARDS or CARM?

Do analysts prefer ARDS or CARM?

Which has higher earnings & valuation, ARDS or CARM?

Is ARDS or CARM more profitable?

Does the media prefer ARDS or CARM?

Which has more risk & volatility, ARDS or CARM?

Summary

How does Carisma Therapeutics compare to Navidea Biopharmaceuticals?

Does the media favor NAVB or CARM?

Do analysts recommend NAVB or CARM?

Is NAVB or CARM more profitable?

Do insiders and institutionals believe in NAVB or CARM?

Which has stronger earnings & valuation, NAVB or CARM?

Which has more risk & volatility, NAVB or CARM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools